Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Intestinal candidiasis: modern therapeutic tactics].

A R Zlatkina

    Eksperimental'Naia I Klinicheskaia Gastroenterologiia = Experimental & Clinical Gastroenterology
    |March 24, 2007
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Diagnosis and treatment policy in chronic enteropathies].

    Terapevticheskii arkhiv·2003
    Same author

    [Abdominal pain in functional disorders of the gastrointestinal tract: basic mechanisms and ways of elimination].

    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology·2002
    Same author

    [Outpatient treatment of irritable colon syndrome: quality of diagnosis and treatment].

    Klinicheskaia meditsina·2002
    Same author

    [Chronic colitis].

    Klinicheskaia meditsina·1999
    Same author

    [The principles of treating patients with chronic pancreatitis].

    Terapevticheskii arkhiv·1999
    Same author

    [The irritable bowel syndrome (its clinical picture, diagnosis and treatment)].

    Terapevticheskii arkhiv·1997

    Intestinal candidiasis is a significant medical issue, diagnosed by identifying Candida in bowel tissue. Natamycin (Pimafucin) is the recommended treatment, acting locally without systemic side effects.

    Area of Science:

    • Gastroenterology
    • Mycology
    • Internal Medicine

    Context:

    • Intestinal candidiasis presents a growing challenge across multiple medical disciplines, including gastroenterology, gynecology, dentistry, and surgery.
    • This condition is intrinsically linked to systemic candidiasis affecting other organs.
    • Accurate diagnosis relies on identifying the filamentous form of Candida in bowel mucosal biopsies.

    Purpose:

    • To outline the diagnostic criteria for intestinal candidiasis.
    • To identify the primary therapeutic agent for this condition.

    Summary:

    • The diagnostic approach for intestinal candidiasis involves microscopic examination of bowel mucosal tissue to detect the pseudomycelial form of Candida.
    • Natamycin, marketed as Pimafucin, is the drug of choice for treating intestinal candidiasis.

    Related Experiment Videos

  • Pimafucin exerts a localized effect within the intestinal lumen, preventing systemic absorption and minimizing adverse effects.

    • Impact:

    • Establishes a clear diagnostic pathway for intestinal candidiasis.
    • Highlights the efficacy and safety of Natamycin (Pimafucin) as a targeted treatment.
    • Reduces the burden of intestinal candidiasis across various medical specialties through effective management.